ethyl 2,3-dioxobutanoate 2-[4-(trifluoromethyl)phenyl]hydrazone | 327090-20-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2,3-dioxobutanoate 2-[4-(trifluoromethyl)phenyl]hydrazone
• 英文别名: ethyl 3-oxo-2-(2-(4-(trifluoromethyl)phenyl)hydrazono)butanoate；ethyl 3-oxo-2-[[4-(trifluoromethyl)phenyl]hydrazinylidene]butanoate
• CAS: 327090-20-0
• 化学式: C₁₃H₁₃F₃N₂O₃
• 分子量: 302.253
• InChiKey: HVNADQSNVOBGGL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.63
• 重原子数：
  21.0
• 可旋转键数：
  5.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  67.76
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  ethyl 2,3-dioxobutanoate 2-[4-(trifluoromethyl)phenyl]hydrazone 在 吗啉 、 1,2,3,4,5,6,7,8-八硫杂环辛烷 、 sodium acetate 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 0.32h， 生成 ethyl 5-amino-4-oxo-3-(4-(trifluoromethyl)phenyl)-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylate
  参考文献：
  名称：

  Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure–activity relationship leads to selection of candidates with desirable in vivo properties

  摘要：

  Previous studies demonstrated that members of the aminothienopyridazine (ATPZ) class of tau aggregation inhibitors exhibit a promising combination of in vitro activity as well as favorable pharmacokinetic properties (i.e., brain-penetration and oral bioavailability). Here we report the synthesis and evaluation of several new analogues. These studies indicate that the thienopyridazine core is essential for inhibition of tau fibrillization in vitro, while the choice of the appropriate scaffold decoration is critical to impart desirable ADME-PK properties. Among the active, brain-penetrant ATPZ inhibitors evaluated, 5-amino-N-cyclopropyl-3-(4-fluorophenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide (43) was selected to undergo maximum tolerated dose and one-month tolerability testing in mice. The latter studies revealed that this compound is well-tolerated with no notable side-effects at an oral dose of 50 mg/kg/day. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.05.027
• 作为产物：
  描述：

  对三氟甲基苯胺 、 乙酰乙酸乙酯 在 盐酸 、 sodium nitrite 、 sodium acetate 作用下， 以 水 、 乙醇 为溶剂， 反应 2.5h， 生成 ethyl 2,3-dioxobutanoate 2-[4-(trifluoromethyl)phenyl]hydrazone
  参考文献：
  名称：

  作为新型 CXCR2 拮抗剂的 1,2,4-triazol-3-one 衍生物和哒嗪酮衍生物的设计、合成和抗肿瘤评价

  摘要：

  趋化因子受体 2 (CXCR2) 是含有谷氨酸-亮氨酸-精氨酸序列的趋化因子 CXCs (ELR + CXCs) 的受体。近年来，CXCR2靶向治疗策略在癌症治疗中取得了长足的进步。CXCR2拮抗剂可阻断CXCLs/CXCR2轴，广泛用于调节免疫细胞迁移、肿瘤转移、细胞凋亡和血管生成。在此，基于概念验证设计和合成了两个系列的新型CXCR2小分子抑制剂，包括 1,2,4-triazol-3-one 衍生物1-11和哒嗪酮衍生物12-22 。哒嗪酮衍生物18表现出良好的 CXCR2 拮抗活性（10 μM 时为 69.4 ± 10.5 %Inh），并在 MDA-MB-231 细胞中表现出显着的抗癌转移活性，在 HUVEC 中表现出显着的抗血管生成活性。此外，值得注意的是，18在MDA-MB-231细胞的抗增殖试验中与索拉非尼表现出明显的协同作用。此外，18显示 MDA-MB-231 细胞中 PI3K

  DOI：

  10.1016/j.ejmech.2021.113812

文献信息

• 2-Aminothienopyridazines as Novel Adenosine A₁ Receptor Allosteric Modulators and Antagonists
  作者：Gemma N. Ferguson、Celine Valant、James Horne、Heidi Figler、Bernard L. Flynn、Joel Linden、David K. Chalmers、Patrick M. Sexton、Arthur Christopoulos、Peter J. Scammells

  DOI：10.1021/jm800557d

  日期：2008.10.9

  A pharmacophore-based screen identified 32 compounds including ethyl 5-amino-3-(4-tert-butylphenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxylate (8) as a new allosteric modulator of the adenosine A(1) receptor (A(1)AR). On the basis of this lead, various derivatives were prepared and evaluated for activity at the human A(1)AR. A number of the test compounds allosterically stabilized agonist-receptor-G protein ternary complexes in dissociation kinetic assays, but were found to be more potent as antagonists in subsequent functional assays of ERK1/2 phosphorylation. Additional experiments on the most potent antagonist, 13b, investigating A(1)AR-mediated [S-35]GTP gamma S binding and [H-3]CCPA equilibrium binding confirmed its antagonistic mode of action and also identified inverse agonism. This study has thus identified a new class of A(1)AR antagonists that can also recognize the receptor's allosteric site with lower potency.
• Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure–activity relationship leads to selection of candidates with desirable in vivo properties
  作者：Carlo Ballatore、Alex Crowe、Francesco Piscitelli、Michael James、Kevin Lou、Gabrielle Rossidivito、Yuemang Yao、John Q. Trojanowski、Virginia M.-Y. Lee、Kurt R. Brunden、Amos B. Smith

  DOI：10.1016/j.bmc.2012.05.027

  日期：2012.7

  Previous studies demonstrated that members of the aminothienopyridazine (ATPZ) class of tau aggregation inhibitors exhibit a promising combination of in vitro activity as well as favorable pharmacokinetic properties (i.e., brain-penetration and oral bioavailability). Here we report the synthesis and evaluation of several new analogues. These studies indicate that the thienopyridazine core is essential for inhibition of tau fibrillization in vitro, while the choice of the appropriate scaffold decoration is critical to impart desirable ADME-PK properties. Among the active, brain-penetrant ATPZ inhibitors evaluated, 5-amino-N-cyclopropyl-3-(4-fluorophenyl)-4-oxo-3,4-dihydrothieno[3,4-d]pyridazine-1-carboxamide (43) was selected to undergo maximum tolerated dose and one-month tolerability testing in mice. The latter studies revealed that this compound is well-tolerated with no notable side-effects at an oral dose of 50 mg/kg/day. (C) 2012 Elsevier Ltd. All rights reserved.
• Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists
  作者：Xun Zhang、Jingyi Luo、Qinyuan Li、Qilei Xin、Lizhen Ye、Qingyun Zhu、Zhichao Shi、Feng Zhan、Bizhu Chu、Zijian Liu、Yuyang Jiang

  DOI：10.1016/j.ejmech.2021.113812

  日期：2021.12

  therapy. CXCR2 antagonists could block CXCLs/CXCR2 axis, and are widely used in regulating immune cell migration, tumor metastasis, apoptosis and angiogenesis. Herein, two series of new CXCR2 small-molecule inhibitors, including 1,2,4-triazol-3-one derivatives 1–11 and pyridazinone derivatives 12–22 were designed and synthesized based on the proof-to-concept. The pyridazinone derivative 18 exhibited

  趋化因子受体 2 (CXCR2) 是含有谷氨酸-亮氨酸-精氨酸序列的趋化因子 CXCs (ELR + CXCs) 的受体。近年来，CXCR2靶向治疗策略在癌症治疗中取得了长足的进步。CXCR2拮抗剂可阻断CXCLs/CXCR2轴，广泛用于调节免疫细胞迁移、肿瘤转移、细胞凋亡和血管生成。在此，基于概念验证设计和合成了两个系列的新型CXCR2小分子抑制剂，包括 1,2,4-triazol-3-one 衍生物1-11和哒嗪酮衍生物12-22 。哒嗪酮衍生物18表现出良好的 CXCR2 拮抗活性（10 μM 时为 69.4 ± 10.5 %Inh），并在 MDA-MB-231 细胞中表现出显着的抗癌转移活性，在 HUVEC 中表现出显着的抗血管生成活性。此外，值得注意的是，18在MDA-MB-231细胞的抗增殖试验中与索拉非尼表现出明显的协同作用。此外，18显示 MDA-MB-231 细胞中 PI3K